Will GnRH antagonists improve prostate cancer treatment?

被引：44
作者：
Huhtaniemi, IlPo [1 ]
White, Richard [2 ]
McArdle, Craig A. [3 ]
Persson, Bo-Eric [4 ,5 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Dept Reprod Biol, London W12 0NN, England
[2] Ferring Res Inst Inc, San Diego, CA 92121 USA
[3] Univ Bristol, Henry Wellcome Labs Integrat Neurosci & Endocrino, Bristol BS1 3NY, Avon, England
[4] Elisabethsjukhuset, S-75226 Uppsala, Sweden
[5] Ferring Int Ctr, CH-1162 St Prex, Switzerland
来源：
TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2009年 / 20卷 / 01期
关键词：
GONADOTROPIN-RELEASING-HORMONE; FOLLICLE-STIMULATING-HORMONE; MESSENGER-RNA EXPRESSION; LUTEINIZING-HORMONE; OPEN-LABEL; AGONIST TREATMENT; RAPID DESENSITIZATION; LEUPROLIDE ACETATE; SERUM TESTOSTERONE; BETA-ARRESTINS;
D O I：
10.1016/j.tem.2008.09.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Androgen ablation forms a basis for treating prostate cancer and is achieved either by surgical castration, or pharmacologically using oestrogens, anti-androgens and/or gonadotropin-releasing hormone (GnRH) analogues. GnRH antagonists (or blockers) offer a new means of treatment by directly blocking GnRH receptors. Advantages of GnRH antagonists include lack of the initial stimulation of gonadotropin and testosterone production, lack of gonadotropin microsurges and sustained follicle-stimulating hormone suppression; disadvantages include increased histamine release. This review discusses advantages and disadvantages of the GnRH antagonists currently in development, in light of receptor physiology and pre-clinical and clinical data. Comparative clinical trials will ultimately establish their efficacy in comparison to other pharmacotherapies. Therefore, continuing development and refinement is needed to improve prostate cancer treatment.
引用
收藏
页码：43 / 50
页数：8
相关论文
共 80 条
  • [1] ADAMOPOULOS DA, 1994, FERTIL STERIL, V62, P155
  • [2] RAPID DESENSITIZATION OF GNRH-STIMULATED INTRACELLULAR SIGNALING EVENTS IN ALPHA-T3-1 AND HEK-293 CELLS EXPRESSING THE GNRH RECEPTOR
    ANDERSON, L
    MCGREGOR, A
    COOK, JV
    CHILVERS, E
    EIDNE, KA
    [J]. ENDOCRINOLOGY, 1995, 136 (11) : 5228 - 5231
  • [3] Differential regulation of gonadotropin subunit gene promoter activity by pulsatile gonadotropin-releasing hormone (GnRH) in perifused LβT2 cells:: Role of GnRH receptor concentration
    Bédécarrats, GY
    Kaiser, UB
    [J]. ENDOCRINOLOGY, 2003, 144 (05) : 1802 - 1811
  • [4] Targeting FSH in androgen-independent prostate cancer: Abarelix for prostate cancer progressing after orchiectomy
    Beer, TM
    Garzotto, M
    Eilers, KM
    Lemmon, D
    Wersinger, EM
    [J]. UROLOGY, 2004, 63 (02) : 342 - 347
  • [5] Eligard® 6:: Achieving optimal testosterone control with the convenience of a twice-a-year formulation
    Berges, Richard
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (15) : 840 - 845
  • [6] BETCHETZ PE, 1978, SCIENCE, V202, P631
  • [7] Degarelix compared to leuprolide depot 7.5 mg in a 12-month randomised, open-label, parallel-group phase III study in prostate cancer patients
    Boccon-Gibod, L.
    Klotz, L.
    Schroeder, H.
    Andreou, C.
    Persson, B. E.
    Cantor, P.
    Jensen, J. K.
    Kold, Olesen T.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 205 - 205
  • [8] Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix
    Broqua, P
    Riviere, PJM
    Conn, PM
    Rivier, JE
    Aubert, ML
    Junien, JL
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) : 95 - 102
  • [9] Regulation of gonadotropin subunit gene transcription
    Burger, LL
    Haisenleder, DJ
    Dalkin, AC
    Marshall, JC
    [J]. JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2004, 33 (03) : 559 - 584
  • [10] Chengalvala Murty V., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P399, DOI 10.2174/1568011033482251
12345678